Stay updated with breaking news from Nasdaq Dice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Guggenheim lowered shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) from a buy rating to a neutral rating in a report published on Wednesday morning, The Fly reports. A number of other analysts also recently commented on the company. Cantor Fitzgerald downgraded DICE Therapeutics from an overweight rating to a neutral rating in a research […]
DICE Therapeutics (NASDAQ:DICE – Get Rating) had its price objective boosted by Wells Fargo & Company from $38.00 to $48.00 in a research note issued to investors on Tuesday morning, The Fly reports. Several other research analysts have also commented on DICE. TD Cowen started coverage on DICE Therapeutics in a report on Wednesday, March […]
DICE Therapeutics (NASDAQ:DICE – Get Rating) had its price objective increased by Wells Fargo & Company from $38.00 to $48.00 in a research note released on Tuesday, The Fly reports. DICE has been the topic of a number of other reports. TD Cowen began coverage on shares of DICE Therapeutics in a report on Wednesday, […]
Shares of DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 […]
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 8,010,000 shares, a decrease of 9.0% from the April 30th total of 8,800,000 shares. Currently, 20.8% of the company’s shares are sold short. Based on an average […]